Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 601

1.

Human acute myeloid leukemia blast-derived exosomes in patient-derived xenograft mice mediate immune suppression.

Hong CS, Danet-Desnoyers G, Shan X, Sharma P, Whiteside TL, Boyiadzis M.

Exp Hematol. 2019 Jul 29. pii: S0301-472X(19)30918-X. doi: 10.1016/j.exphem.2019.07.005. [Epub ahead of print]

PMID:
31369790
2.
3.

Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma.

Razzo BM, Ludwig N, Hong CS, Sharma P, Fabian KP, Fecek RJ, Storkus WJ, Whiteside TL.

Carcinogenesis. 2019 Jun 27. pii: bgz124. doi: 10.1093/carcin/bgz124. [Epub ahead of print]

PMID:
31245809
4.

Proteomes of exosomes from HPV(+) or HPV(-) head and neck cancer cells: differential enrichment in immunoregulatory proteins.

Ludwig S, Marczak L, Sharma P, Abramowicz A, Gawin M, Widlak P, Whiteside TL, Pietrowska M.

Oncoimmunology. 2019 Apr 15;8(7):1593808. doi: 10.1080/2162402X.2019.1593808. eCollection 2019.

5.

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT.

Theodoraki MN, Yerneni S, Gooding WE, Ohr J, Clump DA, Bauman JE, Ferris RL, Whiteside TL.

Oncoimmunology. 2019 Apr 24;8(7):1593805. doi: 10.1080/2162402X.2019.1593805. eCollection 2019.

6.

Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma.

Ludwig S, Hong CS, Razzo BM, Fabian KPL, Chelvanambi M, Lang S, Storkus WJ, Whiteside TL.

Cancer Immunol Immunother. 2019 Jul;68(7):1133-1141. doi: 10.1007/s00262-019-02348-2. Epub 2019 May 28.

PMID:
31139925
7.

Publisher Correction: Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment.

Shu S, Yang Y, Allen CL, Maguire O, Minderman H, Sen A, Ciesielski MJ, Collins KA, Bush PJ, Singh P, Wang X, Morgan M, Qu J, Bankert RB, Whiteside TL, Wu Y, Ernstoff MS.

Sci Rep. 2019 Mar 15;9(1):4959. doi: 10.1038/s41598-018-37179-1.

8.

Optimization of cell culture conditions for exosome isolation using mini-size exclusion chromatography (mini-SEC).

Ludwig N, Razzo BM, Yerneni SS, Whiteside TL.

Exp Cell Res. 2019 May 15;378(2):149-157. doi: 10.1016/j.yexcr.2019.03.014. Epub 2019 Mar 8.

PMID:
30857972
9.

An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY.

Cancer Cell. 2019 Jan 14;35(1):33-45.e6. doi: 10.1016/j.ccell.2018.12.001.

PMID:
30645975
10.

The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update.

Whiteside TL.

Expert Rev Mol Diagn. 2018 Dec;18(12):1029-1040. doi: 10.1080/14737159.2018.1544494. Epub 2018 Nov 9.

PMID:
30406709
11.

Harmonization of exosome isolation from culture supernatants for optimized proteomics analysis.

Abramowicz A, Marczak L, Wojakowska A, Zapotoczny S, Whiteside TL, Widlak P, Pietrowska M.

PLoS One. 2018 Oct 31;13(10):e0205496. doi: 10.1371/journal.pone.0205496. eCollection 2018.

12.

Molecular and Functional Profiles of Exosomes From HPV(+) and HPV(-) Head and Neck Cancer Cell Lines.

Ludwig S, Sharma P, Theodoraki MN, Pietrowska M, Yerneni SS, Lang S, Ferrone S, Whiteside TL.

Front Oncol. 2018 Oct 12;8:445. doi: 10.3389/fonc.2018.00445. eCollection 2018.

13.

Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence.

Theodoraki MN, Hoffmann TK, Jackson EK, Whiteside TL.

Clin Exp Immunol. 2018 Oct;194(1):67-78. doi: 10.1111/cei.13157. Epub 2018 Sep 19.

PMID:
30229863
14.

Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment.

Shu SL, Yang Y, Allen CL, Maguire O, Minderman H, Sen A, Ciesielski MJ, Collins KA, Bush PJ, Singh P, Wang X, Morgan M, Qu J, Bankert RB, Whiteside TL, Wu Y, Ernstoff MS.

Sci Rep. 2018 Aug 27;8(1):12905. doi: 10.1038/s41598-018-31323-7. Erratum in: Sci Rep. 2019 Mar 15;9(1):4959.

15.

Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells.

Ludwig N, Yerneni SS, Razzo BM, Whiteside TL.

Mol Cancer Res. 2018 Nov;16(11):1798-1808. doi: 10.1158/1541-7786.MCR-18-0358. Epub 2018 Jul 24.

PMID:
30042174
16.

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.

Wolf GT, Moyer JS, Kaplan MJ, Newman JG, Egan JE, Berinstein NL, Whiteside TL.

Onco Targets Ther. 2018 Jun 28;11:3731-3746. doi: 10.2147/OTT.S165411. eCollection 2018. Review.

17.

Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer.

Theodoraki MN, Yerneni SS, Brunner C, Theodorakis J, Hoffmann TK, Whiteside TL.

Oncoscience. 2018 Apr 29;5(3-4):75-87. doi: 10.18632/oncoscience.410. eCollection 2018 Mar.

18.

Exosomes in acute myeloid leukemia inhibit hematopoiesis.

Boyiadzis M, Whiteside TL.

Curr Opin Hematol. 2018 Jul;25(4):279-284. doi: 10.1097/MOH.0000000000000439. Review.

PMID:
29846239
19.

Microvessel density in head and neck squamous cell carcinoma.

Szafarowski T, Sierdzinski J, Szczepanski MJ, Whiteside TL, Ludwig N, Krzeski A.

Eur Arch Otorhinolaryngol. 2018 Jul;275(7):1845-1851. doi: 10.1007/s00405-018-4996-2. Epub 2018 May 10.

20.

Polyfunctionality of CD4+ T lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma.

Doescher J, Jeske S, Weissinger SE, Brunner C, Laban S, Bölke E, Hoffmann TK, Whiteside TL, Schuler PJ.

Strahlenther Onkol. 2018 May;194(5):392-402. doi: 10.1007/s00066-018-1289-z. Epub 2018 Apr 16.

PMID:
29663037
21.

Lymphoma exosomes reprogram the bone marrow.

Whiteside TL.

Blood. 2018 Apr 12;131(15):1635-1636. doi: 10.1182/blood-2018-02-830497. No abstract available.

22.

Potential roles of tumor-derived exosomes in angiogenesis.

Ludwig N, Whiteside TL.

Expert Opin Ther Targets. 2018 May;22(5):409-417. doi: 10.1080/14728222.2018.1464141. Epub 2018 Apr 26. Review.

23.

The emerging role of plasma exosomes in diagnosis, prognosis and therapies of patients with cancer.

Whiteside TL.

Contemp Oncol (Pozn). 2018 Mar;22(1A):38-40. doi: 10.5114/wo.2018.73882. Epub 2018 Mar 5. Review.

24.

FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.

Whiteside TL.

Expert Opin Ther Targets. 2018 Apr;22(4):353-363. doi: 10.1080/14728222.2018.1451514. Epub 2018 Apr 10. Review.

25.

Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma.

Sharma P, Ludwig S, Muller L, Hong CS, Kirkwood JM, Ferrone S, Whiteside TL.

J Extracell Vesicles. 2018 Feb 15;7(1):1435138. doi: 10.1080/20013078.2018.1435138. eCollection 2018.

26.

Introducing a New Series: Immunotherapy Facts and Hopes.

Melero I, Sznol M, Tessmer MS, Whiteside TL, Wolchok JD.

Clin Cancer Res. 2018 Apr 15;24(8):1773-1774. doi: 10.1158/1078-0432.CCR-18-0408. Epub 2018 Feb 23. No abstract available.

27.

Separation of plasma-derived exosomes into CD3(+) and CD3(-) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients.

Theodoraki MN, Hoffmann TK, Whiteside TL.

Clin Exp Immunol. 2018 Jun;192(3):271-283. doi: 10.1111/cei.13113. Epub 2018 Mar 12.

28.

Profiling of plasma-derived extracellular vesicles cargo for diagnosis of pancreatic malignancy.

Whiteside TL.

Ann Transl Med. 2017 Dec;5(24):501. doi: 10.21037/atm.2017.10.23. No abstract available.

29.

Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment.

Whiteside TL.

Semin Immunol. 2018 Feb;35:69-79. doi: 10.1016/j.smim.2017.12.003. Epub 2017 Dec 27. Review.

30.

Exosomes in Cancer: Another Mechanism of Tumor-Induced Immune Suppression.

Whiteside TL.

Adv Exp Med Biol. 2017;1036:81-89. doi: 10.1007/978-3-319-67577-0_6. Review.

PMID:
29275466
31.

Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients.

Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL.

Clin Cancer Res. 2018 Feb 15;24(4):896-905. doi: 10.1158/1078-0432.CCR-17-2664. Epub 2017 Dec 12.

32.

Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.

Geskin LJ, Akilov OE, Kwon S, Schowalter M, Watkins S, Whiteside TL, Butterfield LH, Falo LD Jr.

Cancer Immunol Immunother. 2018 Mar;67(3):423-434. doi: 10.1007/s00262-017-2090-z. Epub 2017 Dec 4.

PMID:
29204699
33.

The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy.

Whiteside TL.

Future Oncol. 2017 Dec;13(28):2583-2592. doi: 10.2217/fon-2017-0343. Epub 2017 Dec 4. Review.

34.

Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomes.

Whiteside TL.

Transl Cancer Res. 2017 Dec;6(Suppl 9):S1406-S1408. doi: 10.21037/tcr.2017.10.32. No abstract available.

35.

Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia.

Hong CS, Sharma P, Yerneni SS, Simms P, Jackson EK, Whiteside TL, Boyiadzis M.

Sci Rep. 2017 Oct 31;7(1):14684. doi: 10.1038/s41598-017-14661-w.

36.

Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms.

Muller L, Simms P, Hong CS, Nishimura MI, Jackson EK, Watkins SC, Whiteside TL.

Oncoimmunology. 2017 Jul 19;6(8):e1261243. doi: 10.1080/2162402X.2016.1261243. eCollection 2017.

37.

Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL.

Cytotherapy. 2017 Oct;19(10):1225-1232. doi: 10.1016/j.jcyt.2017.07.008. Epub 2017 Aug 30.

PMID:
28864289
38.

Response commentary: exosomes vs microvesicles in hematological malignancies.

Whiteside TL, Boyiadzis M.

Leukemia. 2017 Oct;31(10):2277. doi: 10.1038/leu.2017.248. Epub 2017 Aug 4. No abstract available.

39.

Head and Neck Carcinoma Immunotherapy: Facts and Hopes.

Whiteside TL.

Clin Cancer Res. 2018 Jan 1;24(1):6-13. doi: 10.1158/1078-0432.CCR-17-1261. Epub 2017 Jul 27. Review.

40.

Isolation of Biologically Active Exosomes from Plasma of Patients with Cancer.

Hong CS, Funk S, Whiteside TL.

Methods Mol Biol. 2017;1633:257-265. doi: 10.1007/978-1-4939-7142-8_16.

PMID:
28735492
41.

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).

Butterfield LH, Zhao F, Lee S, Tarhini AA, Margolin KA, White RL, Atkins MB, Cohen GI, Whiteside TL, Kirkwood JM, Lawson DH.

Clin Cancer Res. 2017 Sep 1;23(17):5034-5043. doi: 10.1158/1078-0432.CCR-16-3016. Epub 2017 May 23.

42.

Stimulatory role of exosomes in the context of therapeutic anti-cancer vaccines.

Whiteside TL.

Biotarget. 2017 May;1. pii: 5. doi: 10.21037/biotarget.2017.05.05. Epub 2017 May 25. No abstract available.

43.

Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Ludwig S, Floros T, Theodoraki MN, Hong CS, Jackson EK, Lang S, Whiteside TL.

Clin Cancer Res. 2017 Aug 15;23(16):4843-4854. doi: 10.1158/1078-0432.CCR-16-2819. Epub 2017 Apr 11.

44.

Targeting adenosine in cancer immunotherapy: a review of recent progress.

Whiteside TL.

Expert Rev Anticancer Ther. 2017 Jun;17(6):527-535. doi: 10.1080/14737140.2017.1316197. Epub 2017 Apr 27. Review.

PMID:
28399672
45.

Exosomes carrying immunoinhibitory proteins and their role in cancer.

Whiteside TL.

Clin Exp Immunol. 2017 Sep;189(3):259-267. doi: 10.1111/cei.12974. Epub 2017 May 19. Review.

46.

The emerging roles of tumor-derived exosomes in hematological malignancies.

Boyiadzis M, Whiteside TL.

Leukemia. 2017 Jun;31(6):1259-1268. doi: 10.1038/leu.2017.91. Epub 2017 Mar 21. Review.

PMID:
28321122
47.

Extracellular vesicles isolation and their biomarker potential: are we ready for testing?

Whiteside TL.

Ann Transl Med. 2017 Feb;5(3):54. doi: 10.21037/atm.2017.01.62. No abstract available.

48.

The role of tumor-derived exosomes in epithelial mesenchymal transition (EMT).

Whiteside TL.

Transl Cancer Res. 2017 Feb;6(Suppl 1):S90-S92. doi: 10.21037/tcr.2017.02.13. No abstract available.

49.

Tumor-Derived Exosomes and Their Role in Tumor-Induced Immune Suppression.

Whiteside TL.

Vaccines (Basel). 2016 Oct 20;4(4). pii: E35. Review.

50.

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H.

J Neurooncol. 2016 Dec;130(3):517-527. Epub 2016 Sep 13.

Supplemental Content

Loading ...
Support Center